Cost‐effectiveness of biological treatment sequences for fistulising Crohn’s disease across Europe-Reference-Cited by-同舟云学术

Cost‐effectiveness of biological treatment sequences for fistulising Crohn’s disease across Europe

Published:2018-03 Issue:2 Volume:6 Page:310-321
ISSN:2050-6406
Container-title:United European Gastroenterology Journal
language:en
Short-container-title:United European Gastroenterol. j.

Author:

Baji Petra¹,Gulácsi László¹,Brodszky Valentin¹,Végh Zsuzsanna²,Danese Silvio³,Irving Peter M⁴,Peyrin‐Biroulet Laurent⁵,Schreiber Stefan⁶,Rencz Fanni¹⁷,Lakatos Péter L²,Péntek Márta¹

Affiliation:

1. Department of Health EconomicsCorvinus University of BudapestBudapestHungary

2. 1st Department of MedicineSemmelweis UniversityBudapestHungary

3. Department of GastroenterologyIstituto Clinico HumanitasMilanItaly

4. IBD CentreGuy's and St Thomas' NHS Foundation TrustLondonUK

5. Department of GastroenterologyNancy University HospitalVandœuvre‐lès‐NancyFrance

6. Department Internal Medicine IKiel UniversityUniversity HospitalKielGermany

7. Semmelweis University Doctoral School of Clinical MedicineBudapestHungary

Publisher

Wiley

Subject

Gastroenterology,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1177/2050640617708952

Reference36 articles.

1. The Economic and Quality-of-Life Burden of Crohn’s Disease in Europe and the United States, 2000 to 2013: A Systematic Review

2. Health Care Costs of Complex Perianal Fistula in Crohn’s Disease

3. Effects of fistula on healthcare costs and utilization for patients with Crohnʼs disease treated in a managed care environment

4. Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease

5. Infliximab Maintenance Therapy for Fistulizing Crohn's Disease

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patients' Perspectives, Experiences, and Concerns With Perianal Fistulae: Insights From Online Targeted-Disease Forums;CROHNS COLITIS 360;2023

2. Infliximab Pricing in International Economic Evaluations in Inflammatory Bowel Disease to Inform Biologic and Biosimilar Access Policies: A Systematic Review;MDM Policy & Practice;2023-01

3. Cost-effectiveness Analysis of Subcutaneous Infliximab for Inflammatory Bowel Diseases in Sequential Biologic Treatment;Inflammatory Bowel Diseases;2022-08-09

4. Cost-effectiveness Analysis of Universal Cystoscopy at the Time of Benign Laparoscopic Hysterectomy;Journal of Minimally Invasive Gynecology;2021-08

5. First-line biologic treatment of inflammatory bowel disease during the first 12 months after diagnosis from 2010 to 2016: a Norwegian nationwide registry study;Scandinavian Journal of Gastroenterology;2021-07-28